Application of cell-free RNA in liquid biopsy
Cell-free RNA in blood offers complementary cancer detection and monitoring capabilities to existing DNA tests, positioning it as a future core component of liquid biopsy.
This Critical Reviews in Oncology/Hematology review systematically examines cfRNA molecular features, analytical technologies, and clinical applications including early cancer detection, molecular subtyping, and pregnancy complication prediction—framing cfRNA as a functional complement to ctDNA. Key emerging dimensions including fragmentomics, epitranscriptomics, and microbial cfRNA are addressed alongside standardisation challenges; cfRNA is positioned as a future core technology for early detection and personalised monitoring.
What the study was
- Study design
- comprehensive_review
- Category
- early_cancer_detection_liquid_biopsy
- Maturity
- Validated
- Journal
- Critical Reviews in Oncology/Hematology
Why it surfaced
Comprehensive cfRNA review in Critical Reviews covers the technical and clinical landscape for an emerging liquid biopsy modality complementary to ctDNA; useful for pipeline awareness. Score 5 (N=2, D=1, P=1, E=1) for solid review without original data.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.